Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Author:
Publisher
Oxford University Press (OUP)
Subject
Gastroenterology,General Medicine
Link
http://academic.oup.com/ecco-jcc/article-pdf/6/2/143/1240782/6-2-143.pdf
Reference25 articles.
1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group;Targan;N Engl J Med,1997
2. Infliximab for the treatment of fistulas in patients with Crohn's disease;Present;N Engl J Med,1999
3. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002
4. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease;Rutgeerts;Gastroenterology,2004
5. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease;Schnitzler;Inflamm Bowel Dis,2009
Cited by 120 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease;The American Journal of the Medical Sciences;2024-09
2. Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn’s and Colitis (IRCC);PLOS ONE;2024-07-11
3. Impact of sex and socioeconomic status on the likelihood of surgery, hospitalization, and use of medications in inflammatory bowel disease: a systematic review and meta-analysis;Systematic Reviews;2024-06-24
4. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study;The Lancet Gastroenterology & Hepatology;2024-06
5. Factors Predicting Loss of Remission in Crohn’s Disease Patients in Endoscopic Remission in the Real World;Journal of Clinical Gastroenterology;2024-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3